ArticleRMD open2022

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial.

Byeong-Zu Ghang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.